SUVEN Life Sciences

News Release

Suven Revenue up by 15%; PAT up by 28% for the year ended March 2018

HYDERABAD, INDIA (15 May' 2018) – SUVEN LIFE Sciences Limited, a biopharmaceutical company specialized in CRAMS for global life science companies and drug discovery and developmental activities in Central Nervous System disorders, today announced its audited financial results for the quarter and year ended 31st March 2018. The audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 15th May' 2018 at Hyderabad.

Financial Highlights for the 4th Quarter ended March' 2018 (QoQ):

Growth in income	INR 2229 Mn vs 1669 Mn - up by 34%
Growth in PAT	INR 623 Mn vs 346 Mn - up by 80%
Growth in EBIDTA	INR 1003 Mn vs 547 Mn – up by 83%

Financial Highlights for the year ended March' 2018:

Growth in income	INR 6485 Mn vs 5656 Mn - up by 15%
Growth in PAT	INR 1584 Mn vs 1235 Mn - up by 28%
Growth in EBIDTA	INR 2562 Mn vs 1864 Mn - up by 37%

Suven's expenses on innovative R&D in Drug Discovery stood at INR 585 Mn (previous year INR 649 Mn) constituting 9.02% on revenue for the year ended Mar' 2018.

On consolidation of the accounts of Suven Neurosciences, Inc., USA, the wholly owned subsidiary, the PAT reduced to INR 1234 Mn (previous year INR 871 Mn) and expenditure on R&D increased to INR 902 Mn (previous year INR 991 Mn).

For more information on Suven please visit our Web site at http://www.suven.com

Risk Statement:
Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;

CIN: L24110TG1989PLC009713
6/F, Serene Chambers, Rd#7, Banjara Hills Hyderabad 500034, India
Tel: 9140 2354 1142 Fax: 9140 2354 1152 Email: info@suven.com